Details of the Drug Combinations

General Information of This Drug (ID: DMVXFYE)

Drug Name
Vinorelbine   DMVXFYE
Synonyms
Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

381 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Fluorouracil + Vinorelbine DCOTB31 Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Fluorouracil + Vinorelbine DCLIFSW Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Fluorouracil + Vinorelbine DCRCLI4 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Fluorouracil + Vinorelbine DCUD209 Fluorouracil Breast carcinoma (Cell Line: KPL1) [4]
Fluorouracil + Vinorelbine DCK7RQX Fluorouracil Breast carcinoma (Cell Line: OCUBM) [4]
Fluorouracil + Vinorelbine DCPTGX2 Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [4]
Fluorouracil + Vinorelbine DC3CU0I Fluorouracil Colon carcinoma (Cell Line: RKO) [4]
Fluorouracil + Vinorelbine DCDCXNB Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [4]
Fluorouracil + Vinorelbine DCA0WA1 Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + Vinorelbine DC2RLHK Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [5]
Fluorouracil + Vinorelbine DC7UFC0 Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [5]
Fluorouracil + Vinorelbine DCFNYCJ Fluorouracil Adenocarcinoma (Cell Line: DLD1) [5]
Fluorouracil + Vinorelbine DCPYQ2P Fluorouracil Adenocarcinoma (Cell Line: HCT116) [5]
Fluorouracil + Vinorelbine DCQHWJZ Fluorouracil Adenocarcinoma (Cell Line: HT29) [5]
Fluorouracil + Vinorelbine DCJKC0A Fluorouracil Germ cell tumour (Cell Line: PA1) [5]
Fluorouracil + Vinorelbine DCTWB80 Fluorouracil Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Fluorouracil + Vinorelbine DCEZWQI Fluorouracil Malignant melanoma (Cell Line: A375) [5]
Fluorouracil + Vinorelbine DCA2ANA Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [5]
Fluorouracil + Vinorelbine DCDNTL5 Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [5]
Fluorouracil + Vinorelbine DCUZNZP Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Fluorouracil + Vinorelbine DC9APMC Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Fluorouracil + Vinorelbine DC7PKTN Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + PD-0325901 DCFPPX1 PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + PD-0325901 DC9MINX PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + PD-0325901 DC4AAI1 PD-0325901 Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + PD-0325901 DCS5WSN PD-0325901 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + PD-0325901 DCVWMN4 PD-0325901 Carcinoma (Cell Line: OV90) [4]
Vinorelbine + PD-0325901 DCFKTH4 PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + PD-0325901 DCDLWTC PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + PD-0325901 DCTOWK5 PD-0325901 Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + PD-0325901 DCTQMAM PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + Lapatinib DCVFV0B Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + Lapatinib DC3WWW9 Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + Lapatinib DCBRMXP Lapatinib Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + Lapatinib DCZT9Y7 Lapatinib Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + Lapatinib DC7ZA8X Lapatinib Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + Lapatinib DCIIS61 Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + MK-1775 DC32991 MK-1775 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + MK-1775 DCBLUPJ MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + PMID28460551-Compound-2 DCFCKGW PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + PMID28460551-Compound-2 DCLIF4J PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + PMID28460551-Compound-2 DCTUFZP PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + PMID28460551-Compound-2 DCACILS PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [4]
Vinorelbine + PMID28460551-Compound-2 DCWPF99 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + PMID28460551-Compound-2 DCRVPWE PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + PMID28460551-Compound-2 DCOPW7Z PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + PMID28460551-Compound-2 DC7AKC6 PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + PMID28460551-Compound-2 DCLG88F PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + RTB101 DCF0T30 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + RTB101 DC7UU2U RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + RTB101 DC65TFK RTB101 Breast carcinoma (Cell Line: ZR751) [4]
Vinorelbine + RTB101 DCFHG4M RTB101 Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + RTB101 DCYLZLX RTB101 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + RTB101 DCL8TSS RTB101 Carcinoma (Cell Line: OV90) [4]
Vinorelbine + RTB101 DC113KU RTB101 Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + RTB101 DCIT7OA RTB101 Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + RTB101 DCI9FN5 RTB101 Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + RTB101 DCSEJ9R RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + RTB101 DCYISEV RTB101 Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + SCH-900776 DCVVVT6 SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + SCH-900776 DCKAK5O SCH-900776 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + SCH-900776 DC0T71Q SCH-900776 Carcinoma (Cell Line: OV90) [4]
Vinorelbine + SCH-900776 DC1NK5R SCH-900776 Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + SCH-900776 DCP1GTS SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + SNX-2112 DCM1923 SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + SNX-2112 DCRMX0G SNX-2112 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + SNX-2112 DC6RE84 SNX-2112 Carcinoma (Cell Line: OV90) [4]
Vinorelbine + SNX-2112 DCJ9F7D SNX-2112 Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + SNX-2112 DCNDT9Q SNX-2112 Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + SNX-2112 DC63M2O SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + SNX-2112 DCMTRAE SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + SCH 727965 DC0O6X1 SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + Erlotinib DCPRDRI Erlotinib Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + Erlotinib DCSGBQQ Erlotinib Carcinoma (Cell Line: OV90) [4]
Vinorelbine + Erlotinib DC5YZF4 Erlotinib Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + Erlotinib DC3OJVK Erlotinib Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + Erlotinib DCBQIJI Erlotinib Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + Erlotinib DCWQ4ZO Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + MK-5108 DCL3MZK MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + MK-5108 DC3U39P MK-5108 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + MK-5108 DCVVJGC MK-5108 Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + MK-5108 DC5NZD6 MK-5108 Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + MK-5108 DCUSTTV MK-5108 Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + MK-5108 DCHFE4M MK-5108 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + Ridaforolimus DCW6M2E Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + Ridaforolimus DCCKIZK Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + Ridaforolimus DC6T56A Ridaforolimus Breast carcinoma (Cell Line: ZR751) [4]
Vinorelbine + Ridaforolimus DCD4RGA Ridaforolimus Carcinoma (Cell Line: OV90) [4]
Vinorelbine + Ridaforolimus DC9Z5AZ Ridaforolimus Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + Ridaforolimus DCN47DC Ridaforolimus Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + Ridaforolimus DCVQRLS Ridaforolimus Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + Ridaforolimus DCCRYPP Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + Ridaforolimus DCMU92I Ridaforolimus Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + MK-4827 DCSVNM0 MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + MK-4827 DC1C3VF MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + MK-4827 DCQ6LSR MK-4827 Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + MK-4827 DCERZHW MK-4827 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + MK-4827 DCHZQGL MK-4827 Carcinoma (Cell Line: OV90) [4]
Vinorelbine + MK-4827 DCSMI3Q MK-4827 Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + MK-4827 DC04C30 MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + MK-4827 DCVOPC2 MK-4827 Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + MK-4827 DCMVKO8 MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + MK-4827 DCFU6XM MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + Bortezomib DC1U6MY Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + GSK525762 DCQDQNN GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + GSK525762 DCL6FMR GSK525762 Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + GSK525762 DCTATZU GSK525762 Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + Sorafenib DCX7HTN Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + Sorafenib DCWTFXV Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + Sorafenib DCTEA6G Sorafenib Breast carcinoma (Cell Line: ZR751) [4]
Vinorelbine + Sorafenib DCE4GMO Sorafenib Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + Sorafenib DCP4D30 Sorafenib Carcinoma (Cell Line: OV90) [4]
Vinorelbine + Sorafenib DC4ZUON Sorafenib Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + Sorafenib DC3EP5Y Sorafenib Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + Sorafenib DCIGE1O Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + MK-2206 DCXFCPB MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + MK-2206 DCHHSCV MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + MK-2206 DCQUH50 MK-2206 Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + MK-2206 DC9N7XZ MK-2206 Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + MK-2206 DC666OK MK-2206 Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + MK-2206 DCLL75N MK-2206 Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + MK-2206 DCW93CM MK-2206 Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + MK-2206 DCI8YHU MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + Dasatinib DCT9EID Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + Dasatinib DCI8VHA Dasatinib Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + Dasatinib DC15FNF Dasatinib Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + Dasatinib DC2YWKN Dasatinib Carcinoma (Cell Line: OV90) [4]
Vinorelbine + Dasatinib DCV82VU Dasatinib Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + Dasatinib DCRZ6RO Dasatinib Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + Dasatinib DCPFQKB Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + Dasatinib DC149M7 Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + Ruxolitinib DC0FTTL Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [5]
Vinorelbine + PD-0325901 DC06M2V PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [5]
Vinorelbine + PD-0325901 DC9DPI8 PD-0325901 Adenocarcinoma (Cell Line: A427) [5]
Vinorelbine + PD-0325901 DCJSMXA PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + PD-0325901 DCPR95Y PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + PD-0325901 DC4UAKO PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + PD-0325901 DCPD02U PD-0325901 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + PD-0325901 DCDW8ZZ PD-0325901 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + PD-0325901 DCFV2QL PD-0325901 Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + PD-0325901 DC425AY PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + PD-0325901 DCPCD2U PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + PD-0325901 DCPYYQ4 PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + PD-0325901 DCGCOBV PD-0325901 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + PD-0325901 DCLX6MU PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + PD-0325901 DC9NEPT PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + PD-0325901 DC0UMN9 PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + PD-0325901 DCHOIT6 PD-0325901 Prostate carcinoma (Cell Line: VCAP) [5]
Vinorelbine + LY335979 DCDMJGF LY335979 Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11) [5]
Vinorelbine + Lapatinib DCYY5WT Lapatinib Adenocarcinoma (Cell Line: CAOV3) [5]
Vinorelbine + Lapatinib DCUSXHB Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + Lapatinib DC7828V Lapatinib Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + Lapatinib DCRB3JB Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + Lapatinib DCIKW7T Lapatinib Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + Lapatinib DCYY3HD Lapatinib Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + Lapatinib DCAUFJC Lapatinib Amelanotic melanoma (Cell Line: A2058) [5]
Vinorelbine + Lapatinib DCJXB51 Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + Lapatinib DCO56IC Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + Lapatinib DCUWRSU Lapatinib Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + Lapatinib DC2978F Lapatinib Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + Lapatinib DC96ESD Lapatinib Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + Lapatinib DCWIPFJ Lapatinib Malignant melanoma (Cell Line: UACC62) [5]
Vinorelbine + Lapatinib DC52WPT Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + Lapatinib DCP8BDX Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Lapatinib DCCL93F Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + MK-1775 DC2SARV MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + MK-1775 DCBZZK5 MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + MK-1775 DCVZ16M MK-1775 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + MK-1775 DC9W253 MK-1775 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + MK-1775 DC12MU8 MK-1775 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + MK-1775 DCHLNHA MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + MK-1775 DCAFR89 MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + PMID28460551-Compound-2 DCKCNT7 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [5]
Vinorelbine + PMID28460551-Compound-2 DCFLDFX PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + PMID28460551-Compound-2 DC7X7Q5 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + PMID28460551-Compound-2 DCJT3GX PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + PMID28460551-Compound-2 DCYFCJL PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + PMID28460551-Compound-2 DCW76I7 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + PMID28460551-Compound-2 DCRPI8B PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + PMID28460551-Compound-2 DCQCLA9 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + PMID28460551-Compound-2 DCV6FDS PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [5]
Vinorelbine + PMID28460551-Compound-2 DCRKDCW PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + PMID28460551-Compound-2 DCDJYOB PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + PMID28460551-Compound-2 DCLZ8LY PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + PMID28460551-Compound-2 DCLDN11 PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + PMID28460551-Compound-2 DCTO214 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + PMID28460551-Compound-2 DCT4CVM PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + PMID28460551-Compound-2 DCNUJF6 PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + PMID28460551-Compound-2 DCJ6IKD PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [5]
Vinorelbine + PMID28460551-Compound-2 DCY6N5M PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + Panobinostat DCT6JSN Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Vinorelbine + RTB101 DCZEDNJ RTB101 Adenocarcinoma (Cell Line: OVCAR3) [5]
Vinorelbine + RTB101 DCXYZPH RTB101 Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + RTB101 DCCBYMY RTB101 Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + RTB101 DCXON7B RTB101 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + RTB101 DC24MQE RTB101 Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + RTB101 DC7SC5X RTB101 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + RTB101 DCXG6YT RTB101 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + RTB101 DCH8HUZ RTB101 Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + RTB101 DCEKEVB RTB101 Amelanotic melanoma (Cell Line: A2058) [5]
Vinorelbine + RTB101 DC5HM33 RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + RTB101 DCAX45X RTB101 Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + RTB101 DCB8YDX RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + RTB101 DC4YWJ8 RTB101 Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + RTB101 DCNUY14 RTB101 Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + RTB101 DC90Q7F RTB101 Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + RTB101 DCWW5WO RTB101 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + RTB101 DCZ9ZAQ RTB101 Malignant melanoma (Cell Line: UACC62) [5]
Vinorelbine + RTB101 DCPHLQ0 RTB101 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + RTB101 DCX16J7 RTB101 Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + RTB101 DCL3MY4 RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + RTB101 DC9WI8S RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + RTB101 DCFAH69 RTB101 Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + SCH-900776 DCZ4121 SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + SCH-900776 DCSD1JX SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + SCH-900776 DC6BBKT SCH-900776 Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + SCH-900776 DCKE1HV SCH-900776 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + SCH-900776 DC2DZNQ SCH-900776 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + SCH-900776 DCYTM57 SCH-900776 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + SCH-900776 DC0Q81I SCH-900776 Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + SCH-900776 DCJVZLO SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + SCH-900776 DCQP0GP SCH-900776 Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + SCH-900776 DCP90PO SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + SCH-900776 DCEEAI1 SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + SCH-900776 DCC51UK SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + SCH-900776 DCJI7KC SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + SNX-2112 DCHMH73 SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [5]
Vinorelbine + SNX-2112 DC7DKNL SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + SNX-2112 DCXX754 SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + SNX-2112 DCARXYR SNX-2112 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + SNX-2112 DCY7GMF SNX-2112 Amelanotic melanoma (Cell Line: A2058) [5]
Vinorelbine + SNX-2112 DCR8TU2 SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + SNX-2112 DCDBH1P SNX-2112 Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + SNX-2112 DCCXUQ9 SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + SNX-2112 DC6RETK SNX-2112 Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + SNX-2112 DCVWSBF SNX-2112 Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + SNX-2112 DCCX72M SNX-2112 Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + SNX-2112 DCL8JPD SNX-2112 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + SNX-2112 DCA3GJX SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + SNX-2112 DCD0RIL SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + SNX-2112 DCTABWZ SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + SNX-2112 DCDOV5M SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + SCH 727965 DCCMQQZ SCH 727965 Adenocarcinoma (Cell Line: A427) [5]
Vinorelbine + SCH 727965 DCNBJRW SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + SCH 727965 DCCUNL4 SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + SCH 727965 DCBEWOB SCH 727965 Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + SCH 727965 DCOW3J3 SCH 727965 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + SCH 727965 DCRSOJG SCH 727965 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + SCH 727965 DC4LVEK SCH 727965 Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + SCH 727965 DCBCKZS SCH 727965 Amelanotic melanoma (Cell Line: A2058) [5]
Vinorelbine + SCH 727965 DC714VI SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + SCH 727965 DC0QSSE SCH 727965 Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + SCH 727965 DCGLC5I SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + SCH 727965 DCY8VA3 SCH 727965 Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + SCH 727965 DCY06NZ SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + SCH 727965 DCIPEG6 SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + SCH 727965 DC8252D SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + SCH 727965 DCJ5M0G SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + SCH 727965 DCYZD7L SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + SCH 727965 DCT5WTM SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + Erlotinib DCTPRB4 Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Vinorelbine + Erlotinib DC58OAH Erlotinib Adenocarcinoma (Cell Line: A427) [5]
Vinorelbine + Erlotinib DCENV0X Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + Erlotinib DC2950Q Erlotinib Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + Erlotinib DCH8S40 Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + Erlotinib DC0AD7U Erlotinib Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + Erlotinib DCOHH5L Erlotinib Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + Erlotinib DCWKBQR Erlotinib Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + Erlotinib DCY3PST Erlotinib Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + Erlotinib DCB384L Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + Erlotinib DCPGC94 Erlotinib Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + Erlotinib DCJQSYV Erlotinib Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + Erlotinib DC3A7FA Erlotinib Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + Erlotinib DCZU8TS Erlotinib Malignant melanoma (Cell Line: UACC62) [5]
Vinorelbine + Erlotinib DCZWOCB Erlotinib Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + Erlotinib DCY63SQ Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Erlotinib DC4ZE43 Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + Erlotinib DCQ5QF0 Erlotinib Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + Erlotinib DC3DWQM Erlotinib Prostate carcinoma (Cell Line: VCAP) [5]
Vinorelbine + MK-5108 DCKFSNI MK-5108 Adenocarcinoma (Cell Line: CAOV3) [5]
Vinorelbine + MK-5108 DCH5AMG MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [5]
Vinorelbine + MK-5108 DCD2YW4 MK-5108 Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + MK-5108 DCB5MGU MK-5108 Adenocarcinoma (Cell Line: NCIH23) [5]
Vinorelbine + MK-5108 DCRZVHL MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + MK-5108 DCPFTOH MK-5108 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + MK-5108 DCY3XYC MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + MK-5108 DCVAL52 MK-5108 Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + MK-5108 DCRU0NP MK-5108 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + MK-5108 DC9S3I1 MK-5108 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + MK-5108 DC27QDM MK-5108 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + MK-5108 DCL02YT MK-5108 Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + Ridaforolimus DCHYD1R Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [5]
Vinorelbine + Ridaforolimus DCWLRQN Ridaforolimus Adenocarcinoma (Cell Line: OVCAR3) [5]
Vinorelbine + Ridaforolimus DCNHA7M Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + Ridaforolimus DCRHGHO Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + Ridaforolimus DCBLG82 Ridaforolimus Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + Ridaforolimus DCFKMUS Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + Ridaforolimus DC6FRYG Ridaforolimus Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + Ridaforolimus DCSN3PF Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [5]
Vinorelbine + Ridaforolimus DCD6DCI Ridaforolimus Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + Ridaforolimus DC5YA49 Ridaforolimus Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + Ridaforolimus DCLJ3AV Ridaforolimus Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + Ridaforolimus DC2UJTM Ridaforolimus Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + Ridaforolimus DCL7OAL Ridaforolimus Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + Ridaforolimus DCZ44U1 Ridaforolimus Malignant melanoma (Cell Line: UACC62) [5]
Vinorelbine + Ridaforolimus DCI9GAS Ridaforolimus Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + Ridaforolimus DCZ1Q71 Ridaforolimus Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + Ridaforolimus DCP26M4 Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + MK-4827 DCS41WW MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + MK-4827 DCR2ZR4 MK-4827 Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + MK-4827 DCIBRTN MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + MK-4827 DCV6A07 MK-4827 Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + MK-4827 DCHGUSB MK-4827 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + MK-4827 DCGOMQV MK-4827 Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + MK-4827 DCHOXZ7 MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + MK-4827 DCU4KVY MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + MK-4827 DCZE4K9 MK-4827 Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + MK-4827 DCU28TH MK-4827 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + MK-4827 DCB5IEW MK-4827 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + MK-4827 DCYKNJH MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + MK-4827 DCVBP23 MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + MK-4827 DCDMU19 MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + Idarubicin DCYWDAZ Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + Idarubicin DCBIS65 Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + Idarubicin DC1G7CM Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + Idarubicin DCNNKFU Idarubicin Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + Idarubicin DC72208 Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Bortezomib DC91ZPZ Bortezomib Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + Bortezomib DC5Z0QB Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + Bortezomib DCP2R0W Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + Bortezomib DCBGZA4 Bortezomib Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + Bortezomib DC3BK7R Bortezomib Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + Bortezomib DC7C8PQ Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Bortezomib DCAB231 Bortezomib Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + GSK525762 DCUHJ11 GSK525762 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + GSK525762 DCKC13J GSK525762 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + GSK525762 DCQLWU8 GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Sorafenib DCOKHRD Sorafenib Adenocarcinoma (Cell Line: A427) [5]
Vinorelbine + Sorafenib DCYERPN Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + Sorafenib DCAYEX9 Sorafenib Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + Sorafenib DC4K0UJ Sorafenib Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + Sorafenib DC3KA9X Sorafenib Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + Sorafenib DCVFCP7 Sorafenib Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + Sorafenib DCTB9FB Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + Sorafenib DCZ55Y7 Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + Sorafenib DC9B535 Sorafenib Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + Sorafenib DC5QKDA Sorafenib Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + Sorafenib DCBGQTG Sorafenib Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + Sorafenib DCR312L Sorafenib Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + Sorafenib DCXPPNL Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + Sorafenib DCJ133U Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Sorafenib DC2UFVD Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + Sorafenib DC652Z4 Sorafenib Prostate carcinoma (Cell Line: VCAP) [5]
Vinorelbine + Sorafenib DCKBTQW Sorafenib Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + MK-2206 DCFBD6M MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + MK-2206 DCLFX4I MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + MK-2206 DCA6KNQ MK-2206 Adenocarcinoma (Cell Line: NCIH23) [5]
Vinorelbine + MK-2206 DCRF8H2 MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + MK-2206 DC7QJSS MK-2206 Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + MK-2206 DCCWDAY MK-2206 Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + MK-2206 DCVDUL2 MK-2206 Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + MK-2206 DCR6E3Q MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + MK-2206 DC67KRX MK-2206 Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + MK-2206 DCNPEC2 MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + MK-2206 DCZKEM4 MK-2206 Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + MK-2206 DC8LJQ4 MK-2206 Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + MK-2206 DCLMBSA MK-2206 Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + MK-2206 DCEMPCB MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + MK-2206 DCP1USN MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + MK-2206 DCEFP9S MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + MK-2206 DC1OFV6 MK-2206 Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + Elacridar DCBSEK2 Elacridar Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11) [5]
Vinorelbine + Dasatinib DCU2YWY Dasatinib Adenocarcinoma (Cell Line: A427) [5]
Vinorelbine + Dasatinib DCZN5T7 Dasatinib Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + Dasatinib DCRP4WH Dasatinib Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + Dasatinib DCTZI33 Dasatinib Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + Dasatinib DCKTIIP Dasatinib Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + Dasatinib DCX8S1N Dasatinib Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + Dasatinib DCTCI2U Dasatinib Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + Dasatinib DCAOOFD Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Dasatinib DCEDYWC Dasatinib Prostate carcinoma (Cell Line: LNCAP) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 381 DrugCom(s)
22 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Afatinib + Vinorelbine DCA6MP6 Afatinib Breast Neoplasms [6]
Capecitabine + Vinorelbine DCCMX4E Capecitabine Breast Cancer [7]
Cyclophosphamide + Vinorelbine DCAB5GY Cyclophosphamide Adult Rhabdomyosarcoma [8]
Docetaxel + Vinorelbine DCTHM2N Docetaxel Lung Cancer [9]
Docetaxel + Vinorelbine DCW95ZL Docetaxel Breast Cancer [10]
Erlotinib + Vinorelbine DCYF1JE Erlotinib Non-Small Cell Lung Cancer [11]
Gemcitabine + Vinorelbine DC6PGA4 Gemcitabine Breast Cancer [12]
HKI-272 + Vinorelbine DC7E9KT HKI-272 Breast Cancer [13]
Ifosfamide + Vinorelbine DC450A4 Ifosfamide Lymphoma [14]
Lapatinib + Vinorelbine DCAUQG4 Lapatinib Breast Cancer [15]
Letrozole + Vinorelbine DC1JH47 Letrozole Breast Cancer [16]
Pazopanib + Vinorelbine DCC2KU5 Pazopanib Metastatic Non Small Cell Lung Cancer [17]
Temozolomide + Vinorelbine DCO152V Temozolomide Metastatic Cancer [18]
Topotecan + Vinorelbine DCYHSU1 Topotecan Lung Cancer [19]
Vinorelbine + Estramustine DC1PQR3 Estramustine Prostate Cancer [20]
Vinorelbine + Atovaquone DCI3BRO Atovaquone Locally Advanced Non-Small Cell Lung Cancer [21]
Gefitinib + Vinorelbine DC19DHY Gefitinib Non Small Cell Lung Cancer [22]
Gemcitabine + Vinorelbine DCXCWIM Gemcitabine Hodgkin's Lymphoma [23]
Rivoceranib + Vinorelbine DC257BZ Rivoceranib Advanced Triple-Negative Breast Cancer [24]
Rivoceranib + Vinorelbine DCHAQ86 Rivoceranib Breast Cancer [25]
Vinorelbine + Pyrotinib DCG0HI7 Pyrotinib Metastatic Breast Cancer [26]
Carboplatin + Vinorelbine DCWJCLB Carboplatin NSCLC [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DrugCom(s)

References

1 Vinorelbine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7105).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT01441596) Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
7 ClinicalTrials.gov (NCT00130507) Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
8 ClinicalTrials.gov (NCT01222715) Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
9 ClinicalTrials.gov (NCT00736814) First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
10 ClinicalTrials.gov (NCT00015938) S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
11 ClinicalTrials.gov (NCT00702182) Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer
12 ClinicalTrials.gov (NCT00128310) Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
13 ClinicalTrials.gov (NCT00706030) Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
14 ClinicalTrials.gov (NCT00006760) Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
15 ClinicalTrials.gov (NCT00513058) Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
16 ClinicalTrials.gov (NCT02802748) Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
17 ClinicalTrials.gov (NCT01060514) Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
18 ClinicalTrials.gov (NCT00026494) Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
19 ClinicalTrials.gov (NCT00287963) Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
20 ClinicalTrials.gov (NCT00151086) Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
21 ClinicalTrials.gov (NCT04648033) Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
22 ClinicalTrials.gov (NCT02319577) GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
23 ClinicalTrials.gov (NCT01884441) Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
24 ClinicalTrials.gov (NCT03254654) Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
25 ClinicalTrials.gov (NCT02768415) Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
26 ClinicalTrials.gov (NCT04963595) Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
27 ClinicalTrials.gov (NCT03656393) To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma